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Abstract
Drug Hypersensitivity reactions can be distinguished in adverse drug events and adverse 
drug reactions. They represent a major problem in the medical scheme, since they are 
often underestimated. Pharmacogenetic analysis demonstrated significant associations 
between emerging hypersensitivity reactions and distinct genes of the HLA complex. 
HLA-mediated hypersensitivity reactions particularly affect skin and liver, however, 
impairment of the bone marrow and kidney function could also be observed. These life 
threatening medical conditions can be attributed to the activation of autologous drug-
specific T-cells. Severe drug hypersensitivity reactions that resemble acute GvHD are 
linked to certain specific HLA alleles. The most common hypersensitivity reactions occur 
after the treatment of HLA-B*57:01+ HIV patients with abacavir and HLA-A*31:01+ or 
B*15:02+ epileptic patients with carbamazepine (CBZ).
Keywords: HLA, hypersensitivity, adverse drug reactions, T-cells, carbamazepine
1. Introduction
The administration of a drug can be accompanied by harmful adverse events such as gas-
trointestinal bleeding or skin rashes (Table 1). The classification of these adverse events is 
illustrated in Figure 1. Adverse events comprise all harmful reactions during drug applica-
tion regardless of a causal link between the drug and the event. If the drug usage is causal 
for the symptoms, the condition is called adverse drug event (ADE) [1–3]. The term ADE 
comprises harm caused by the drug itself as well as harm caused by the use of the drug, for 
instance inappropriate dosages or premature discontinuation of the medication [1]. Mostly, 
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medication errors do not cause any harm in patients, but in some cases ADEs are triggered by 
increased or decreased drug doses [1]. Opioid-intoxication, as for example a morphine over-
dose leads to unconsciousness, hypoventilation and miosis. The probability of an ADE differs 
from substance to substance. The antimitotic nystatin is very unlikely to cause unwanted 
effects, since it is directed against a cell wall component of fungi and mycoplasma. In contrast, 
immunosuppressive medication has a high risk of enabling virus infections and diminishing 
the surveillance of cancer development as the down regulated immune system is no longer 
able to properly cope with the virus or neoplastic cells [4].
However, certain drugs can cause the patient harm despite proper application. Those unin-
tended and harmful reactions to drugs at therapeutic levels are termed adverse drug reactions 
(ADRs) (WHO 1972). They are triggered by the drug itself and not by inappropriate use of 
the drug. In contrast, side-effects are defined as predictable, but distinct from the intended 
effects. They comprise unwanted, as well as positive or irrelevant effects of a drug appearing 
at normal dosage [1, 4].
Table 1. Examples of drugs leading to adverse events.
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These noxious reactions to drugs are caused by distinct mechanisms, thus different forms of 
ADRs are distinguished as illustrated in Figure 2. Dose-dependent and predictable type A 
ADRs are explained by the pharmacological activity of the drug, whereas dose-independent 
type B reactions appear to be idiosyncratic [5].
With >80% the majority of all ADRs are classed among type A reactions that are rarely fatal 
[5, 6]. They are triggered by off-target binding to non-immune receptors, drug-drug interac-
tion or toxicity; thus the clinical picture depends on the drug [7]. For example, nonsteroidal 
Figure 1. Classification of adverse events. Adverse events include all harmful events occurring during treatment with a 
drug without the necessity of a causal link between the drug and the reaction. If the use of medication is causal for the 
reaction, the condition is called adverse drug event. A subform of adverse drug events are adverse drug reactions that 
are triggered by the drug itself despite its appropriate dosage.
Figure 2. Classification of adverse drug reactions. The majority of all ADRs is dose-dependent and predictable type A 
reactions. Type B reactions occur less. The majority of all ADRs is dose-dependent and predictable type A reactions. 
Type B reactions occur less frequent and have a higher mortality. They are subdivided into allergic, pseudoallergic and 
pharmacologic reactions.
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anti-inflammatory drugs (NSAIDs) are likely to cause gastrointestinal bleeding by inhibit-
ing prostaglandin-synthesis, since prostaglandins do not only reduce inflammation, but also 
impede the production of protective mucus in the stomach. Another example are antihis-
tamines of the first generation; being able to cross the blood-brain barrier the H1-receptor-
antagonists also induce sedation by off-target binding.
Because these reactions to drugs are accounted for by their pharmacological mode of action, 
they are dose-dependent. Their emergence is comprehensible and predictable.
Type B ADRs are characterized by direct involvement of the immune system. They occur less 
frequently, but have an increased mortality rate [5, 7]. Type B reactions can affect almost every 
organ, but often feature involvement of the skin, liver and blood cells. The symptoms can be 
systemic as well as restricted to a single organ [8].
The main trigger of such drug hypersensitivity reactions are antibiotics, non-steroidal anti-
inflammatory drugs and antiepileptics [9]. The nucleoside reverse transcriptase inhibitor 
abacavir utilized for treatment of human immunodeficiency virus type I patients leads to a 
severe and life-threatening hypersensitivity syndrome. Those affected individuals develop 
rashes, fever, gastrointestinal symptoms, lethargy, malaise, arthralgia, myalgia or respiratory 
symptoms in the first weeks after initiation of the intake of the drug. Abacavir hypersensitiv-
ity is highly associated with the human leukocyte antigen (HLA) allele HLA-B*57:01 [10, 11]. 
Another example of a type B adverse reaction is the allergy against penicillin. Symptoms 
include sudden anaphylaxis, hypotension, bronchospasm, angioedema and urticarial [12].
Drug hypersensitivity reactions often occur as skin exanthemas [9]. Several clinical pictures 
can be distinguished. Drug reaction with eosinophilia and systemic symptoms (DRESS) is 
known under various names including drug induced delayed multiple organ hypersensitiv-
ity syndrome (DHDMOHS), drug-induced hypersensitivity syndrome (DIHS), drug hyper-
sensitivity syndrome (DHS) and hypersensitivity syndrome (HSS). It is characterized not only 
by cutaneous exanthema, but also by organ involvement, for example hepatitis, arthralgia 
and lymphadenopathy [13]. Danger signs indicating a DRESS are changes in blood count 
revealing eosinophilia or atypical lymphocytes and signs of organ involvement, namely high 
liver enzymes, high kidney values or lymphnode enlargement. At first, DRESS might resem-
ble maculopapular exanthema, but in the course of the reaction it spreads over more than half 
the body [13]. Some drugs are highly suspected to induce DRESS: the antiepileptics carbam-
azepine, oxcarbazepine, lamotrigine phenytoin and phenobarbital, sulfonamides, as well as 
the uricostaticum allopurinol [13].
Other disease patterns are Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis 
(TEN). In these conditions skin blisters and bullae rise, the skin detaches and erosions 
of mucous membrane are found [14]. The patients develop high fever, hypovolemia and 
complications with lung involvement are possible [15]. In SJS, the detachment of skin 
affects less than 10% of the body surface, whereas in TEN more than 30% of body surface 
detaches [16]. Approximately 48% of all TEN patients die due to the disease, for the elderly 
the mortality is 70%. SJS, SJS/TEN and TEN together have an overall mortality of 20–25% 
[15, 17]. In early stages tiny vesicles or crusts and painful or burning skin and mucosa 
Physiology and Pathology of Immunology58
point towards SJS/TEN. Patients are positive for Nikolsky’s sign, but specific laboratory 
parameters do not exist [18]. Medications with a high risk to induce SJS/TEN are the anti-
epileptics carbamazepine, lamotrigine, phenytoin, phenobarbital, some sulfonamides, the 
uricostaticum allopurinol, oxicam-NSAIDs, sulfasalazine and the antiretroviral drug nevi-
rapine. The algorithm of drug causality for EN algorithm (ALDEN) helps to exclude or 
confirm the suspicion of SJS/TEN [19]. Currently, 67% of SJS/TEN-cases in Europe are drug 
induced with allopurinol being the main trigger [20].
Acute generalized exanthematous pustulosis (AGEP) has an acute onset with fever, large ery-
thema and sterile, non-follicular pinhead-sized rapidly appearing pustules. Desquamation 
starts 4 to 10 days later. In AGEP neutrophilia also occurs; usually other internal organs are 
not, while the mucosa is little involved. Drugs associated with AGEP are for example amino-
penicilins, quinolones and pristinamycine [21].
The first step for diagnosis of a drug hypersensitivity reaction is the analysis of the medical 
history of the patient [9]. Therefore, the symptomatology, the chronology of the symptoms, 
additional drug administration and the medical background are parameters to consider for 
a correct assessment [14]. A differential blood count is considered for confirmation of eosin-
ophila in DRESS or neutrophilia in AGEP [9, 13, 22]. The involvement of other organs (liver, 
kidney, heart) is evaluated by investigation of laboratory parameters [13].
Skin tests and drug provocation tests enable in vivo identification of the drug responsible for 
the reactions. Patch tests are a safe method to identify the accountable drug in DRESS medi-
ated by antiepileptics [9]. Nevertheless, patch, prick and intracutaneous skin tests are often 
insensitive, especially in case of non-immediate reactions to beta-lactam antibiotics as peni-
cillin [23]. For drug provocation tests, only performed at specialist centers with resuscitative 
equipment, the administration of the suspected drug takes place under controlled conditions 
[24]. They are controversial, since severe reactions can be triggered [9, 24]. Likewise, provoca-
tion tests are not standardized for delayed reactions [9].
An advantage of in vitro tests is the safety of the patient who is not exposed to the drug. 
Additionally, they enable valuable insight into the pathomechanism of the drug allergy. 
However, in vitro tests are not standardized for all drugs and are not suitable to detect all types of 
drug hypersensitivity [9]. The lymphocyte transformation test (LTT) enables simultaneous test-
ing of many drugs and drug concentrations [9]. Measurement of proliferation of drug- specific 
T-cells stimulated with the drug in question is enabled by incorporation of 3H-thymidine [25]. 
The sensitivity of LTTs varies depending on the clinical manifestation and the drug, in AGEP 
and DRESS it is higher, as well as for beta-lactam antibiotics and antiepileptics. LTTs for SJS 
should be performed in the acute phase, whereas for DRESS the resolution phase has highest 
sensitivity. The number of cells releasing cytokines upon stimulation with the suspected drug 
can be determined by enzyme-linked immunosorbent spot assay (ELISpot) [25]. Upregulation 
of CD69 can be observed via flow cytometry, but this procedure is difficult to standardize [9]. 
When considering transitory peaks and degradation, cytokine synthesis and secretion can indi-
cate hypersensitivity reactions. Measurement is possible via enzyme-linked immunosorbent 
assay, ELISpot and flow cytometry. Cytotoxicity can be determined equally [9]. Another test is 
Physiology and Pathology of Drug Hypersensitivity: Role of Human Leukocyte Antigens
http://dx.doi.org/10.5772/intechopen.72133
59
the basophil activation test (BAT) that can identify IgE-mediated reactions [26]. Combinations of 
these tests are currently best in order to diagnose a drug hypersensitivity reaction.
There are several approaches to divide drug hypersensitivity into classes depending on the 
time when first symptoms emerge, the type of immune mechanism or drug or the mode of 
drug action with immune cells [7]. The latter is composed of three groups (see Figure 2): 
Allergic reactions involve the innate and the adaptive immune system, pharmacologic reac-
tions are exclusively triggered by T-cells, whereas pseudoallergic reactions are mediated by 
the innate immune system [7].
In detail, an allergic reaction to drugs is explained by the hapten/prohapten model where 
the drug itself or a reactive metabolite bind covalently to a high molecular weight pro-
tein. Thus, even small molecules that should not be recognized by the immune system 
become immunogenic [27–32]. The drug-carrier molecule can either activate the innate 
immune system via pattern recognition receptors or cells of the adaptive immune system 
react to the newly formed antigen after processing and presentation on HLA molecules [7]. 
Because of the hapten binding to multiple proteins, these allergic reactions are very hetero-
geneous [7, 29, 33]. A typical characteristic of allergic reactions is the immediate reaction 
of the patient due to the IgE-meditated urticaria, angioedema, rhinitis, bronchospasm and 
anaphylactic shock [34]. Drug allergies can also be triggered by IgG or T-cells [7]. Allergy 
against penicillin for example can manifest as IgE-mediated hypersensitivity reaction or as 
a delayed T-cell response [33, 35, 36].
Pseudoallergic type B reactions include mast cell and granulocyte activation, as well as 
involvement of enzymes and co-factors. Hence, the basis of those reactions is not a drug- or 
 antigene-specific sensitization [7], but direct stimulation of effector cells [9]. NSAIDs do not 
only inhibit prostaglandin-synthesis, but also lead to increased amounts of leukotrienes that 
mediate inflammation. Therefore, the intake of NSAIDs can also result in asthma and rhinitis 
or angioedema [37].
Pharmacological reactions are characterized by noncovalent off-target binding of the drug or 
a metabolite to immune receptors. This excludes binding to the peptides presented by HLA 
molecules. Instead, the drug binds to either the T-cell receptor (TCR) or an HLA molecule, 
both are extremely polymorphic [7]. Abacavir hypersensitivity reactions belong to this cat-
egory, since the drug binds to the peptide binding groove of HLA-B*57:01 [38].
2. The relevance of ADEs and ADRs
In consequence of the thalidomide disaster the world health organization (WHO) started the 
Program for International Drug Monitoring with the objective to improve the safety of medi-
cations [39]: In the early 60s of the last century the drug thalidomide that was sold under vari-
ous names all over the world made history [40]. It was advertised as a sedative, tranquilizer 
and antiemetic without side-effects especially suited for pregnant women [41, 42]. By the end 
of 1960 first doubts emerged concerning toxic effects of the drug [43] but it was not until 1961 
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that its teratogenicity was stated [44–47]. Over time several adverse effects became apparent 
with peripheral neuropathy being the most frequent in patients taking thalidomide for long-
term [48]. Also rashes and constipation turned out to be unexpected effects of the drug [40, 49].
When thalidomide was withdrawn in most countries in 1961–1962, more than 10,000 children 
with partially severe malformation had already been born [41, 42]. The number of serious 
cases was boosted by the demeanor of the manufacturer Grünenthal favoring the continued 
sale of the drug over informing the public of the toxic effects the company was aware of since 
1959 [50]. This led to more consciousness about ADRs and other drug-related problems as for 
example medication errors or misuse/abuse of medicines and the raise of pharmacovigilance.
ADRs are an expensive burden on public health, they are under-diagnosed and under-
reported [6, 51]. Already 30 years ago people began to wonder about unintended reactions to 
medication in hospitals. Initially, the question arose which method might be most successful 
in detecting such event [52]. The studies spotted remarkable observations: It was revealed that 
86% of cases went unreported in Sweden [53], whereas in Canada under-reporting reached as 
much as 96% [54]. This might be due to the methods used to identify ADEs or due to unaware-
ness of reporting systems [39]. There are different approaches to improve patient safety by 
early recognition and prevention of ADEs including voluntary reports and computer-based 
monitoring. Traditional detection methods as voluntary reporting are inconvenient and have 
the disadvantage of relying on the commitment of physicians and nurses [55]. Already in 
1991 Classen, Pestotnik [55] reported that their computerized surveillance of ADEs drastically 
elevated their detection and reporting. Based on information about abrupt discontinuation 
of drugs, antidote ordering and anomalous laboratory values, the computer program recog-
nized 641 of 731 ADEs in 36,653 patients, whereas only 9 of those ADEs were revealed by the 
traditional detection methods [55]. This result is coincident with other publications reporting 
that physicians only identified a third of ADRs notified by automatic signals generated from 
laboratory signals [56] and that half of true-positive alerts were unrecognized prior to the 
warning [57].
Evans, Pestotnik [58] stated that the type and the intensity of an ADE had implications on the 
length and costs of the stay in hospital. While patients without ADEs stayed for an average of 
5 days, patients experiencing a type A or type B reaction had prolonged stays of 14 or 17 days, 
respectively. Hence, the costs of hospitalization increased by 3.7- or 4.8-fold for these patients. 
Moderate ADEs led to extended stays of 13 days and a 3.6-fold increase in costs; severe ADEs 
prolonged the stay to an average of 20 days and caused a 6-fold increase in costs.
Different studies considered 30–50% of all ADEs [2, 59] to be preventable, whereas others 
appraised 50–80% of all ADRs to be avoidable [6, 51, 56, 60, 61]. Interestingly, severe reac-
tions were more frequently classified as preventable than mild reactions [2, 59]. Nevertheless, 
about 3% of all deaths and approximately 6.4% of hospital-fatalities in the UK are caused by 
ADRs [62]. There are several reasons for those preventable ADEs to happen. Too high doses 
of drugs in relation to the patient’s age, renal function, weight and underlying disease were 
identified by Evans, Pestotnik [58] as a main reason for the moderate reactions. Errors during 
ordering and administration were found causal for most ADEs by Bates, Cullen [59]; other 
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studies claimed ADEs to emerge more likely due to errors while ordering and monitoring, 
whereas dispensing and administration of the drugs rarely caused the reactions [2].
As a possible strategy to improve patient safety, several authors have demonstrated significant 
prevention of ADEs by the application of pharmacy alerts for known drug allergies [57, 58], 
as well as presence of pharmacists on ward rounds, improved monitoring and education of 
prescribing [6, 63].
3. Mechanisms of type B ADRs
Most drugs are not antigenic due to their small size (<1000 Da), however, by forming a hapten 
or prohapten through covalent binding to carrier proteins the drug-protein complex becomes 
chemically reactive and can subsequently trigger an immune response. Prohaptens are pre-
cursor haptens that become reactive by metabolizing the drug to generate active haptens. In 
order to cause an allergic reaction, these hapten complexes have to be processed by antigen 
presenting cells (APC). After migration to the local lymphoid tissue, sensitization of naïve 
T-cells or stimulation of B cells can occur. Primed T-cells proliferate and act as effector T-cells 
and may also aide the differentiation of B cells to plasma cells that produce drug-hapten 
specific IgE or IgG antibodies, depending on the presence of either Th1 or Th2 helper cells. 
Accordingly, allergic hypersensitivity reactions are categorized into four types (Type I–IV) 
based on the classification system established by Gell & Coombs [7].
4. Antibody mediated hypersensitivity reactions (Type I–III)
Type I–III reactions (Figure 3) occur if drug-specific B cells differentiate into antibody pro-
ducing plasma cells through CD4+ Th2 cell stimulation. In the case of Type I reactions these 
plasma cells produce IgE antibodies. Many of these reactions are caused by antibiotics of the 
β-lactam family (e.g. penicillin and its derivatives) that can lead to symptoms ranging from 
mild skin reaction to the life threatening anaphylactic shock. In the case of penicillin, the anti-
biotic binds covalently to high-molecular weight proteins such as albumin [64] thus forming 
a molecule complex that can be recognized by IgE antibodies. During sensitization, these IgE 
antibodies bind to mast cells in tissues and basophiles in the blood via the FcεRI receptor. 
Subsequent cross-linking of the IgE antibody with the antigen elicits the type I reaction result-
ing in the release of histamines, leukotrienes and serotonin as well as prostaglandin causing 
allergic symptoms [14]. Type I reactions are immediate reactions that take place directly after 
administration of the drug or up to 2 hours later. Typically, clinical manifestations contain 
symptoms such as urticaria, mild skin rashes and anaphylactic shock.
In non-immediate type II and type III reactions symptoms emerge 5 to 21 days after admin-
istration of the drug [14], however, first symptoms are usually observed after 24 to 48 hours. 
Both types are primarily IgG-mediated. Damage mediated by tissue-specific IgG or IgM 
antibodies is the basis for type II reactions: On exposure, the drug forms a hapten with a 
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self-protein thus creating a modified self-protein. Binding of IgG or IgM to the modified self-
tissue is followed by activation of normal immunoglobulin effectors. Drug specific type II 
reactions are mostly associated with the destruction of red blood cells and platelets, where 
the respective drug bound to the cell surface serves as an antigenic target for IgG antibod-
ies leading to antibody-dependent cell-mediated cytotoxicity (ADCC). Consequently, the cell 
bound antibody then triggers clearance of the cell from the circulation by macrophages or NK 
cells that recognize the Fc part of the IgG antibodies via the FcγRIII (CD16) surface receptor. 
Examples are hemolytic anemia as an adverse reaction to methyldopa or leukopenia in the 
case of aminopyrine.
Type III hypersensitivity reactions are caused by soluble drug-haptens that form immune 
complexes with IgG antibodies [14]. Larger aggregates are fixed by complement und consecu-
tively cleared by phagocytes, however, smaller immune complexes deposit at local tissue sites 
where FcR binding on leukocytes and mast cells induces an inflammatory response leading 
to increased vascular permeability. Conditions that arise from type III reactions are serum 
sickness (especially β-lactams), drug-induced lupus erythematosus and thrombocytopenia 
(quinidine) or vasculitis or even DRESS (minocycline).
5. T-cell-mediated drug hypersensitivity (type IV) without prior 
drug exposure
Type IV reactions (Figure 3) take the longest time to develop, ranging from 2 days up to 20 days 
until first symptoms emerge. Symptoms include mild conditions such as MPE to more severe 
conditions such as TEN or SJS. Type IV ADRs are T-cell mediated drug hypersensitivity reac-
tions based on the erroneous T-cell activation through HLA molecules on the surface of endog-
enous cells. Different modes of activation can be distinguished, whether the antigen is formed 
by binding of the drug to a self-protein, thus creating a foreign antigen for T-cell recognition 
Figure 3. Type I – IV drug-related hypersensitivity reactions.
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(allergic), or the drug interfering directly or indirectly with the interaction between T-cell 
receptor (TCR) and HLA (pharmacological). The processing and interference of presentation 
by APCs leads to an immunostimulatory potential that manifests in delayed hypersensitivity 
reactions [65] and although direct recognition of the drug as an immunogen is more common 
with non-human protein therapeutics [66], most small molecules are not direct immunogens. 
Their potential for eliciting a hypersensitivity reaction is explained by either of the following 
models (Figure 4): Hapten model, p-i model and altered peptide repertoire model [7].
6. The hapten/prohapten model
The hapten model is based on the binding of small chemicals to proteins or peptides and thus 
generating new antigenic determinants. These complexes are processed by APCs in lymphoid 
tissues and generate antigenic hapten-peptides that have the ability to stimulate T-cells in an 
HLA dependent manner. Examples are sensitive reactions to β-lactam antibiotics. Penicillin, 
for instance, is known to bind extracellular proteins, in particular to lysine residues of serum 
albumin [67]. In the case of penicillin, haptenated peptides are presented to CD4+ T-cells by 
HLA-DRB1 [68]. Chemically inert drugs may also produce delayed hypersensitivity reactions 
if the metabolite of the otherwise non-reactive drug becomes active. An example here is sulfa-
methoxazole. In the liver CYP2C9 modifies sulfamethoxazole into hydroxylamine metabolite 
that is reactive, converts spontaneously to nitroso sulfamethoxazole that readily binds protein 
cysteine residues of extracellular and cellular proteins [69].
7. The p-i model
After it became apparent that the hapten model is not sufficient to explain the diversity of 
different hypersensitivity reactions, the pharmacological interaction with immune receptors 
Figure 4. Overview of the models explaining T cell-mediated hypersensitivity.
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(p-i) model and the altered peptide repertoire model were proposed. The p-i model postulates 
that binding of the drug itself to either the TCR or the HLA molecule may elicit the hyper-
sensitivity reaction [70]. Such binding is independent from metabolites and processing by 
APCs and additionally, the binding is non-covalent and therefore potentially weak [71]. This 
means the p-i mechanism is reversible and binding can occur at the interaction sites of the 
TCR-HLA complex as well as outside of the binding regions. In either case, the drug-binding 
interferes with the interaction between the HLA molecule and the TCR. In general, as part 
of the p-i concept, the drug binding has to induce functional changes and the mechanism 
is immediate because it directly interferes with the already present system. Also, the innate 
immune system and B cells are not involved because antigen processing is not involved in the 
p-i concept. Because these structures are allele specific and therefore specific to highly poly-
morphic regions, this immune response is only observed for carriers of certain HLA alleles. 
Additionally, the drug can bind in the groove and change the features of the pockets in the 
peptide binding groove, so that even though a correct peptide is presented the change in over-
all conformity can lead to T-cell activation. Examples for the p-i concept are the interaction of 
allopurinol with HLA-B*58:01 where binding of the drug leads to immediate T-cell activation 
that was not limited to a specific TCR Vβ pattern [72].
8. The altered peptide repertoire model
The relation between delayed hypersensitivity reactions and HLA associations is further 
explained by the altered peptide repertoire model. This concept is based on the binding of 
the drug inside the peptide binding groove during HLA assembly in the ER [38]. However, 
binding in the peptide binding groove leads to altered peptide specificity and thus changes 
the presented self-repertoire. Consequently, an erroneous T-cell response is triggered because 
the TCR does not recognize these altered peptides as self anymore. This model was first based 
on findings that were made from the peptide elution studies and crystal structure of HLA-
B*57:01 with abacavir [38, 73]. The structure demonstrated that Abacavir resides within the C, 
D, E and F pocket of the peptide binding groove influencing the peptide binding capacity of 
HLA-B*57:01 leading to a shift in the presented repertoire. For endogenous T-cells, this poses 
an allogenic antigen prompting an immune response similar to the mechanism of allograft 
rejection and graft versus host disease (GvHD).
9. HLA-mediated ADRs
Through genome-wide association studies an increasing number of associations between 
certain allelic HLA variants and drug-hypersensitivities could be identified [74]. In order to 
secure safer treatment of patients, it is essential to understand the underlying mechanisms 
[75]. The discovery of an association between ADRs and certain HLA alleles represented an 
important medical step towards the prediction and prophylaxis of Type B ADRs. These par-
ticular HLA-mediated hypersensitivity reactions are highly specific; hence HLA subtypes that 
are linked to ADRs represent biomarkers for the determination of individual medications. 
HLA molecules bind and present peptides of the intracellular proteomic content; their origin 
Physiology and Pathology of Drug Hypersensitivity: Role of Human Leukocyte Antigens
http://dx.doi.org/10.5772/intechopen.72133
65
is determined by the health status of the cell. During pathological conditions, HLA molecules 
can bind peptides of non-self origin and display targets for effector cells that scan peptide-
HLA complexes on the cellular surface for self- / non-self discrimination. The HLA-system 
is extremely polymorphic. For most HLA genes several allelic variants exist, most of them 
are distinguished by amino acid (AA) exchanges within the peptide binding region (PBR). 
Structural alterations within the PBR result in the selection and binding of peptides exhibit-
ing differential features (origin, sequence, length). Every single peptide alters the accessible 
surface of a given peptide-HLA complex for recognition by an effector cell receptor. T-cell 
responses can be triggered through the recognition of single AA mismatches that alter the 
biophysical state of the PBR and thus the features of the bound peptides, the heavy chain and 
hence the mode of peptide loading and/or the half life time of the pHLA complexes.
The first discovered and most prominent example is the association between the antiretroviral 
drug abacavir and HLA B*57:01 [10]. Abacavir is a nucleoside analogue of guanosine, it inhibits 
competitively the reverse transcriptase of the retrovirus HIV. 5–8% of treated patients develop 
hypersensitivity reactions, comprising fever, fatigue, gastrointestinal symptoms up to life 
threatening, multiorgan diseases. HLA-restricted hypersensitivity reactions triggered by aba-
cavir are verified to be CD8+ T-cell-mediated [76], using a broad repertoire of TCR clonotypes 
[75, 77]. Thereby, Abacavir-induced CD8+ T-cell activation is elicited by an altered repertoire 
of self-peptides, presented by HLA B*57:01 [78]. Due to the high incidence of HLA B*57:01, all 
patients are typed for HLA class I molecules prior to therapy in order to protect patients from 
hypersensitivity syndrome and the pharmaceutical industry from its associated costs [79, 80].
Another example is the HLA-associated ADR induced by Allopurinol. This inhibitor of xan-
thine oxidase, applied in gout and hyperuricemia, causes severe cutaneous adverse reactions 
in patients carrying the HLA B*58:01 gene [81].
CBZ-induced ADRs are strongly associated with two HLA genotypes, HLA B*15:02 in Han 
Chinese [82, 83] and HLA A*31:01 in Caucasian and Japanese population [84, 85]. Both HLA 
alleles differ substantially in their AA composition and their immune function. However, 
a strong discrimination between the clinical outcome of HLA-B*15:02 or A*31:01 positive 
patients following CBZ administration can be observed. The anticonvulsive drug CBZ is com-
monly used to treat epilepsy, trigeminal neuralgia, bipolar disorder or chronic pain. In 5% 
of cases, therapy with CBZ is discontinued because of adverse drug reactions. Nevertheless, 
CBZ is commonly applied due to its therapeutic success and its comparable tolerability. 
CBZ-induced ADRs vary in their severity from mild maculopapular exanthema (MPE) or 
hypersensitivity syndrome (HSS) to life-threatening Stevens-Johnson syndrome (SJS) or toxic 
epidermal necrolysis (TEN) [86, 87]. The ADR-causing mechanism, triggered by CBZ, is not 
yet completely discovered. SJS and TEN are caused by cytotoxic CD8+ T-cells [88], MPE and 
HSS also involve skin-infiltrating CD4+ T-cells. These CD4+ T-cells damage the skin by secret-
ing inter alia perforin and granzyme B [89]. Interestingly, HLA B*15:02 is associated with SJS/
TEN, but not with MPE or HSS [86]. In contrast, HLA A*31:01 is associated with HSS, MPE 
and SJS/TEN [90]. Associations are detected in Japanese, Han Chinese as well as in European 
ancestry [84–86]. The prevalence of this allele is 2–5% in Northern European population, 2% 
in Han Chinese population and 9% in Japanese population [84]. According to the broad range 
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of HLA A*31:01-restricted CBZ-induces ADRs, different types of CBZ-specific T-cells were 
isolated of patient’s peripheral blood: CD3+/CD4+, CD3+/CD8+ as well as CD3+/CD4+/CD8+ 
T-cells [91, 92].
Thereby, further association between CBZ-specific CD4+ T-cell response and the HLA class 
II molecules HLA DR and DP could be detected. Especially, HLA-DRB1*04:04 seems to be 
associated with CBZ-induced ADR driven by CD4+ T-cells. This HLA allele occurs commonly 
in a haplotype block with HLA A*31:01 in Caucasians [92, 93]. While HLA A*31:01-restricted 
CBZ-induced ADRs are widely unexplained [90], there are several suggestions about the 
mechanism of HLA B*15:02-restricted CBZ-induced ADRs. STS/TEN are triggered by cyto-
toxic T-cells inter alia via perforins, granzyme B and granulysin [94]. There are reasonable 
presumptions, that T-cell activation occurs via direct interaction of CBZ with the immunore-
ceptor [95], in accordance with the p-i model [96, 75]. Confirmed T-cell activation indepen-
dently of metabolism of CBZ and intracellular antigen processing, supports this hypothesis 
[97, 95]. In contrast, presentation of an altered self-peptide repertoire by HLA-B*15:02 due to 
CBZ-exposure is reported, leading to the presumption, the T-cell receptor is activated accord-
ing to altered repertoire model [38]. Additionally, the presence of HLA B*15:02 is not a suf-
ficient characteristic to elicit CD8+ T-cell response, since not all carriers are responders [35, 98]. 
However, restricted usage of TCR clonotype is required for immune activation [99]. Thus, it 
could be illustrated that only HLA B*15:02-typed patients with T-cells, expressing the TCR Vβ 
11-ISGSY, react hypersensitive to CBZ [100].
The mechanism of HLA-meditated hypersensitivity reactions to drugs are not completely 
understood, yet. Polymorphic residues within a given HLA molecule affect their conforma-
tion and their bound peptides. Open questions remain i) how does the drug interact with 
selected residues of the HLA-molecules heavy chain?, ii) is the reaction triggered by the drug 
itself or by a metabolite?, iii) can non-responders to a drug be attributed to the presence or a 
lack of given TCRs and their immunological vitality?
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